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ASSOCIATIONS BETWEEN TRAITS (BLOOD PRESSURE AND BODY HEIGHT 
GROWTH) AND REPRODUCTIVE TIMING RELATED GENETIC VARIANTS FROM 
GENOME-WIDE ASSOCIATION STUDIES  
 
 
Recent genome-wide association studies (GWAS) have identified many common genetic variants 
that are associated with women’s reproductive timing characteristics including ages at menarche 
and at natural menopause. However, the associations of these variants with other human health-
related phenotypes such as blood pressure, cancer, diabetes, obesity, and body height growth have 
not been well studied. No published studies to our knowledge have directly assessed the genetic 
influence of reproductive timing related variants on the aforementioned common traits. A better 
understanding of pleiotropic effects of these variants is important because it will help elucidate 
the precise mechanisms of common traits/diseases such as hypertension which have not been 
fully understood so far, and give clues for developing better solutions for disease prevention and 
treatment. We, therefore, conducted three studies to explore genetic variant effects on blood 
pressure and body height growth. In the first study, we analyzed data from a local cohort of 601 
healthy adolescents from Indianapolis schools. Mixed effect model analysis revealed that 11 
reproductive related single nucleotide polymorphisms (SNPs) were significantly associated with 
blood pressure in the study subjects. In order to assess if these genetic effects extended to the 
adult blood pressure, we performed the second study to investigate the genetic effect on blood 
pressure in adults. We used the summary statistics obtained from the two large international 
GWAS consortia, the Blood Pressure Consortium and the ReproGen Consortium. Bivariate 
analyses showed that more than 100 SNPs were associated with both blood pressure and 
reproductive timing. As the blood pressure development is closely related to somatic growth, we 
conducted the third study to exam the genetic effect of reproductive-timing related variants on the 
linear growth from the aforementioned local cohort. We identified 8 genetic variants significantly 
 v 
associated with the catch-up of linear growth in the study subjects.  In conclusion, these three 
studies collectively provided evidence in support of the pleiotropic effects of the reproductive 
timing variants, suggesting the common genetic basis underlying the correlated traits.  Future 
research is needed to validate the findings. 
 
 
 Chunyan He, ScD, Chair
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Study 1: Reproductive Timing Related Genetic Variants from Genome-Wide Association 
Studies Are Associated with Blood Pressure in Healthy Adolescents 
 
 
Introduction 
 
Blood pressure (BP) increases in adolescents accompanying rapidly linear body growth after 
reproductive maturity process starts [Ewald, 2016]. Prevalence of prehypertension and 
hypertension is estimated at between 4% and 15%, and between 2% and 5% among adolescents 
[Ewald, 2016].  Unfortunately, many hypertensive children are undiagnosed. Increased blood 
pressure (BP) increases risk of developing long-term health outcomes such as cardiovascular 
diseases and renal impairment [Ewald, 2016].  Commonly known factors for increased BP in 
adolescents include obesity, height, sex, age, genetic predisposition, socioeconomic status, 
cultural influences, physical exercise, and reproductive timing [Ewald, 2016].  
 
With regard to reproductive timing, age at menarche as well as age at natural menopause have 
been associated with increased BP and risk of cardiovascular diseases [Lakshman, 2009; Hu 
1999]. BP increases at an accelerated rate with onset of sexual maturation [Shankar 2005]. Early 
menarche is associated with elevated BP in adolescent and adulthood [Koziel, 2001; 
Dianels,1998].  BP is also known to increase more steeply around age at menopause [Lindquist, 
1982]. Earlier menopause is associated with higher BP [Staessen, 1989; Izumi, 2007], although it 
is still unclear whether menopause accelerates BP increase or increased BP leads to earlier 
menopause. The observed synchronization between reproductive aging and BP increase raises 
questions about the possibility of common regulating mechanisms shared by these processes.   
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We hypothesize that common genetic variants have pleiotropic effects on reproductive aging and 
BP. Although phenotype data suggest an association between reproductive timing and BP 
increase [Shankar, 2005; Koziel, 2001; Dianels,1998; Lindquist, 1982; Staessen,1989; 
Izumi,2007], to date, no published data have directly addressed if reproductive timing related 
genetic variants have a role in hypertension development [Zhang, 2013, Johnson, 2015, Ehret 
2011, Spencer 2013]. It is important to identify genetic variants that predispose subgroups to high 
blood pressure because characterization of genes for hypertension may identify subgroup at 
hypertension risk in the primary prevention, may develop more effective drugs for clinical 
intervention, and monitor the target organ damages such as for reducing the clinical 
complications (e.g., renal failure) [Thiel 2000]. Therefore, we conducted a study to evaluation 
association between BP and SNPs previously identified from GWAS that were associated with 
menarche or menopause associated in healthy adolescents. 
 
Patients and Methods 
 
Study population 
The study subjects were from a longstanding prospective cohort established in 1986 to study 
blood pressure development in children and adolescents. The detailed study design and data 
collection process have been described elsewhere [Pratt, 1989, Tu 2011; Tu 2015].  Briefly, 
healthy children, aged 4-17 years were enrolled from 33 schools in Indianapolis, IN., and were 
followed up 5.4 years on average. Their participation was voluntary. Informed consent was 
obtained from each child as well as from his or her parents or a legal guardian. The study was 
approved by the institutional review board of Indiana University-Purdue University of 
Indianapolis. Self-reported race categories were recorded and validated [Tu 2009; Tu 2014]. 
Children were excluded from the study if they had a history of renal or cardiac disease or diabetes 
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mellitus, or if they took medications that could affect aldosterone secretion or blood pressure 
[Pratt, 1989; Manatunga, 1993; Tu, 2011].  
   
Blood pressure assessment  
Semiannual assessment of blood pressure was conducted. Blood pressure measurements were 
carried out at enrollment and semiannually between 08:00 am and 12:00 pm at the subject's 
school, in some instances in the Indiana University Clinical Research Center, or in the subject's 
home.  BP was measured in the right arm with a random zero sphygmomanometer (Hawksley and 
Sons, Lancing, West Sussex, UK) while the subject was in a seated position. The first and fifth 
Korotkoff sounds were used for systolic and diastolic BP measurements, respectively. Three 
readings were obtained at intervals of at least 2 minutes, and the average of the last two readings 
was used in the analyses. On average, each subject contributed 11 repeated measurements [Pratt, 
1989]. 
 
Blood samples, genotyping and SNP selection 
DNA was extracted for participants with blood samples stored at -20° C.  Genotypes of the 
candidate SNPs were determined using the Sequenom MassArray iPLEX Platform (Sequenom, 
San Diego, CA). The genotyping success rate for each SNP was over 95% [Tu 2015]. Samples 
with missing genotypes higher than 2% were removed from the study. In the retained samples, all 
SNPs were in Hardy–Weinberg equilibrium (P value > 0.05). The allele frequency for each SNP 
in our data was consistent with that reported for populations of European and African descent in 
the International HapMap Project (http://hapmap.ncbi.nlm.nih.gov/).  We selected 46 independent 
SNPs that have been reported to be associated with reproductive time (age at menarche or with 
age at menopause) in meta-analyses of GWAS of women of European ancestry [Elks, 2010; 
Stolk, 2012]. These SNPs were either strongly associated with reproductive time (with reported 
p-value ≤ 1×10−8), or associated with both reproductive time and another adult growth outcome 
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(weight or height).  Based on their associations with age at menarche and other correlated growth 
traits, we further categorized these SNPs into four groups: Group A included 16 SNPs associated 
with age at menarche only [Elks, 2010]; Group B included 8 SNPs associated with both age at 
menarche and adult BMI [Elks, 2010]; Group C included 7 SNPs associated with both age at 
menarche and adult height [Elks, 2010]; and Group D included 15 SNPs associated with 
menopause [Stolk, 2012]. Detailed descriptions of the SNPs are listed in Table 1-1.  
 
Other measure assessments  
Semiannual assessment of growth in height and weight was also conducted in these subjects 
[Manatunga, 1993]. BMI, defined as weight (kilograms)/height (meters)2 was calculated for each 
follow-up visit.  
 
Data Analysis 
Patient characteristics were summarized using sample mean and standard deviation (SD) for 
continuous variables; and sample proportions for discrete variables. During the study period, the 
means were calculated by averaging the measurements for the follow-up period, incorporating the 
repeated measurements on an individual in the standard error. Summary statistics were reported 
for samples stratified by race. The regression analysis was based on longitudinal data collected 
from 601 adolescents (263 blacks and 338 whites) (Pratt, 1989; Tu, 2015). Blood pressure data 
that spanned between ages 5 and 21 years were used in the analyses. Mixed effects models were 
used to examine the associations of SNPs on systolic and diastolic BP at any given age, in black 
and white children.  The models incorporated genetic effects on blood pressure as fixed effects at 
the population level; and subject-specific random effects were incorporated into the model to 
accommodate the potential correlations among measures from the same subject. The association 
between each SNP and measure of blood pressure (systolic and diastolic blood pressure) was 
assessed with adjustment for age, race, sex, and BMI. The models included the main effects of 
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SNP, sex, age, race, BMI, height, and SNP*age interaction. The main effect of SNP was 
estimated by the intercept of the regression line corresponding to the genotype (shift); the age 
effect reflected the rate of BP increase of the reference genotype (slope); and the SNP*age 
interaction assessed whether the increase rate differed by genotype.  Because we did not know the 
real underlying genetic model, we tested dominant, recessive, and additive genetic models. We 
then tested three-way interactions SNP*age*race in data while adjusting for the variable of sex 
and SNP* age*sex in data while adjusting for the variable of race.  These interaction terms 
allowed us to determine the heterogeneity of the genotype effect on BP increase rate between 
males and females and between whites and blacks. In order to control for multiple testing, a 
Bonferroni correction was used based on the number of SNPs in each group. A statistical 
significance threshold of 0.0031, 0.0063, 0.0071 and 0.0033 was applied to Group A, B, C and D, 
respectively. All P values were based on two-sided tests. Genetic associations and interactions 
that remained significant after adjustment for multiple testing were reported. All statistical 
analyses were performed using SAS version 9.2 software (SAS Institute Inc., Cary, NC, USA). 
 
Results 
 
Characteristics of subjects  
Participants consisted of 263 blacks (112 boys and 151 girls) and 338 whites (170 boys and 168 
girls).  At study entry, the average systolic blood pressure (SBP) (mmHg) was higher in black 
girls (103.0) than that in white girls (98.6) (P=0.002). SBP did not differ significantly between 
black boys (104.1) and white boys (100.7) or between sex groups for each of the race groups.  
The average diastolic blood pressure (DBP) (mmHg) did not differ significantly between sex 
groups or race groups (black girls 63.3; black boys 61.9; white girl 60.5; and white boys 60.4).  
The average age, weight, height, and BMI did not differ significantly between sex groups for each 
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of the race groups.  However, blacks were on average older, heavier, and taller than whites, and 
also had a larger average of BMI (P=0.0001).   
 
In the follow-up period, the average SBP continued to be higher in black girls (105.4 mmHg) than 
white girls (102.4 mmHg, P =0.002). Within each of the race groups, the average SBP was higher 
in boys than girls (black boys 108.7 versus black girls 105.4, P=0.0238; white boys 106.7 than 
white girls 102.4, P<0.0001). The average DBP (mmHg) raised marginally significantly amongst 
black girls (63.1) than white girls (61.7) (P=0.05), and did not differ significant between race 
groups for each sex group.  For either whites or blacks, the mean age and BMI did not differ 
significantly between males and females. Black children on average remained heavier, taller, and 
had higher BMI than white children (all P < 0.03).  
 
Genetic associations with blood pressure 
Table 1-3 presents the results for SNPs that were statistically significantly associated with blood 
pressure. Of the 11 SNPs, 10 were statistically associated with increased systolic blood pressure, 
and only one (rs1042367) with increased diastolic blood pressure.  
 
Of the 16 SNPs previously associated with age at menarche (group A), 6 SNPs were associated 
with increased blood pressure (Table 1-3).  We expected that SNPs associated with early 
menarche or natural menopause would be associated with an increased level of blood pressure; 
and found 4 out of the 6 significant SNPs had direction of association with age at menarche as 
expected:  SNP rs10423674 near gene CRTC1 was associated with increased diastolic blood 
pressure in black boys (p=0.001);  Rs1079866 near INHBA was associated with increased systolic 
blood pressure in white girls (p=0.003), whereas rs13187289 near gene PHF15 (p=0.001), and  
rs9635759  near gene CA10 (p=0.002) were associated with increased systolic blood pressure in 
black boys.  In contrast, the remaining 2 SNPs out of these SNPs were not in the direction 
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predicted by individual SNP associations with age at menarche:  SNPs rs17268785 near gene 
CCDC85A[p=0.001] and rs7642134 near gene VGLL3[p=0.003]) were associated with decreased 
systolic blood pressure in black girls.  
 
Of the 8 SNPs previously reported associated with both age at menarche and BMI (group B), only 
rs7647305 near gene ETV5 was associated with increased systolic blood pressure in whites 
(p=0.003 for additive model and 0.0051 for recessive model, respectively) in the direction of 
predicted by the association with age at menarche. 
 
Of the 7 SNPs reportedly associated with both age at menarche and height (group C), 3 SNPs 
were associated with increased blood pressure (Table 1-3).  One of the 3 SNPs showed 
association in the expected direction with age at menarche:  SNP rs6440003 near gene ZBTB38 
was associated with increased systolic blood pressure in white girls (p=0.003). The remaining 2 
SNPs were not in the direction predicted by individual SNP associations with age at menarche:  
SNPs (rs10946808 near gene HIST1H1D and rs757608 near gene TBX2) were associated with 
decreased systolic blood pressure in white boys (p=0.005) and in black boys (p=0.004), 
respectively.  
 
Of the 15 SNPs previously associated with natural menopause age (group D), only rs2153157 
near gene SYCP2L was associated with increased blood pressure (Table 1-3) (p=0.003), in the 
direction predicted by individual SNP associations with natural menopause age.   
 
Race and sex differences  
The statistical modeling demonstrates that the associations between the candidate SNPs and blood 
pressure appeared to be race and sex specific (Table 1-3). Of the 11 SNPs associated with blood 
pressure outcomes, 6 were observed in blacks and 5 in whites.  The heterogeneity test for 
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differences in blood pressure by race was significant for all SNPs (all p<0.05) except rs1079866. 
Among blacks, of the 6 SNPs associated with blood pressure outcomes, 4 SNPs were observed in 
males only and 2 in females only. For whites, of the 5 SNPs associated with blood pressure 
outcomes, 2 SNPS were in both males and females, 2 SNPs in females and 1 in male only.  
  
Discussion 
 
In this study, we hypothesized that common genetic variants that were previously associated with 
reproductive timing have pleiotropic effects both on reproductive timing and BP. We had a 
unique opportunity to examine the effects of reproductive timing related genetic variants on blood 
pressure in in white and black children and adolescents because both genetic variants and blood 
pressure were measured in the Indianapolis healthy children cohort. Mixed effect models revealed 
that 11 reproductive related single nucleotide polymorphisms (SNPs) from previous GWAS were 
significantly associated with blood pressure.  
 
To date, there are limited data on the association between genetic variation related to reproductive 
timing and BP development. Epidemiological data on phenotypes suggests that [Lakshman, 2009; 
Hu 1999; Shankar, 2005; Koziel, 2001; Dianels,1998; Lindquist, 1982; Staessen, 1989; Izumi, 
2007] both factors of age at menarche and age at natural menopause are associated with the risk 
of cardiovascular disease as well as its risk factors including blood pressure (BP). However, no 
study has directly addressed the association between genetic variation related to reproductive 
timing and BP development [Zhang, 2013, Johnson, 2015, Ehret 2011, Spencer 2013].  The 
observed synchronization between reproductive timing and hypertension development raises 
questions about the possibility of common regulating mechanisms shared by these processes.   
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Understanding more about the association between the genetic variants and BP development is 
important for the following reasons.  First, more genes that can contribute to blood pressure 
variation remain to be discovered. The heritability of BP has been estimated to be 30–50%, but 
the genetic variants identified through GWAS together explain less than 3% of the total variance 
of BP. Thus, many of the genetic variants that can explain heritability have been missed in the 
GWAS studies [Munroe, 2013].  Second, any seemly trivial novel gene discovery, even with a 
small magnitude of association, could have utility for disease prevention and clinical 
management. Observational data suggests that a slight increase in BP can execute a great impact 
on health outcome: an increase in SBP by 2 mm Hg increases stroke risk by 10% and coronary 
risk by 7% (Lewington, 2002).  Therefore, any novel genes associated with blood pressure that 
does not seem impressive at first discovery could have great impact on identifying high risk 
population for implementing prevention in early life before full-blown presentations of clinical 
BP and its complications or can be applied in anti-hypertensive medication development. In an 
analog example, a widely used anti-diabetic medication class, glitazones, has been developed 
based on original finding on the gene product of PPARG, a gene with an odds ratio only about 1.2 
for association with type 2 diabetes mellitus [Lohmueller, 2002]. 
 
Our pleiotropic hypothesis was supported by the prospective nature of this longitudinal study 
because, in time sequence, the modeling suggested that the genetic factors predisposed the study 
subjects to the different level of BP increase during the adolescence development period. Our 
hypothesis was also consistent with other studies. A meta-analysis of GWAS showed that genetic 
variants were associated with both age at menopause and serum urate [Zhang, 2013], a trait 
correlated with blood pressure [Johnson, 2015].  In addition, genetic variant intronic ARHGAP42 
rs633185 was reported associated with a blood pressure in a GWAS study [Ehret 2011], and was 
also associated with age at menarche and age at natural menopause in another meta-analysis of 
GWAS [Spencer 2013]. 
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Our results suggested that novel genetic variants associated with both reproductive timing and 
possible pathways that may help explain more of BP variation. Eleven of the 46 SNPs that had 
been found associated with reproductive timing in the previous GWAS were associated with 
blood pressure in our current study. Of note, these 11 SNPs were not included in the recently 
published SNPs associated with blood pressure [GWAS catalog, 2016; Padmanabhan, 2015; and 
Cabrera, 2015]. Interestingly, most of the associations (7 out of 11) were in the direction that 
accelerated increases in BP are associated with a younger age at menarche or age at menopause. 
This consistency in the direction of association suggests that common genetic variants that were 
previously associated with reproductive timing can execute pleiotropic effects both on BP and 
reproductive time in healthy adolescents. A few associations (4 out of 11) were in the opposite 
direction that accelerated increases in BP are associated with earlier sexual maturation or 
menopause. The reason behind these opposite directions cannot be explained by our current 
knowledge.  
 
Note that the observed associations did not appear to be attenuated by BMI in our analysis. This 
suggested that these genetic variants may influence BP differently from the commonly considered 
pathways in which BP is mediated by adiposity [Hall, 2003 and 2010].  In some instances, the 
associations were race-specific and/or gender-specific.  Racial differences in genetic effects may 
reflect differences in underlying BP physiological regulation. A recent review showed that blacks, 
in comparison to whites, appear to have a more expanded plasma volume and sodium (Na2+) 
retention due to an increase in Na2+ reabsorption by the kidney [Tu,2014]. The mechanism for 
genetic effect difference between boys and girls is largely unknown in this study. However, we 
speculated that the difference is attributable to the differential timing of puberty growth spur in 
boys and girls. It was observed that the peak of increase in BP coincided with the peak in 
acceleration of height, and girls had earlier puberty onset as well as earlier increase in peak in BP 
and height than boys [Shankar, 2005; Tu 2009]. The sex difference in genetic effects could be 
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also attributable to sex hormone role difference between girls and boys. At puberty, increase 
testosterone production by testes primarily accounts for development of secondary male sex 
features (SSF) (voice change and pubic hair development) in boys, while the increase in estrogen 
production by ovary in girls primarily for development of secondary female sex features (age at 
menarche and breast development).  Boys presenting earlier SSF were reported to have a higher 
fat-free mass likely due to changes in androgen levels [Rogol, 1994], while girls presenting 
earlier SSF were reported to have a higher fat mass over fat-free mass that coincides with changes 
in estrogen levels (Bandini, 2008). Thus, difference in body composition that is possibly due to 
rise of different responsible sex hormones in puberty [Dunger, 2006] will have conceivably 
different roles in BP development.  Sex hormone per se can also affect BP in other pathways than 
body composition, and the effect of sex hormones vary by sex.  BP increases in menopausal 
women coincides with estrogen decreases but the decrease in estrogen in men after age 50 is not 
remarkable and the magnitude of BP increase is not as much as women [Remington, 2010].  
Estrogen is considered protective against hypertension by activation of the vasodilator pathway 
mediated by nitric oxide and prostacyclin and inhibition of the vasoconstrictor pathway mediated 
by the sympathetic nervous system and angiotensin [Ashraf, 2006].  On the other hand, androgen 
change is in opposite direction for middle aged men and menopausal women:  serum androgen 
level decreases in men after age 50, and increases in postmenopausal women. The changes in 
androgen that occur in opposite direction in men and women are all thought to promote CVD and 
hypertension through pathways of oxidative stress, endothelial dysfunction, and inflammation 
[Reckelhoff, 2011]. Therefore, the race- and sex-specific data above suggested existence of 
complex genetic pathways that may influence BP during rapid growth period.    
 
The precise mechanisms by which these genetic variants affect BP in various pathways are 
unknown and are not within the original scope of this investigation. However, with regard to 
etiology of hypertension, the accumulated data suggest that hypertension in general is likely to be 
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determined by numerous susceptibility genes and involves multiple environmental determinants.  
The most prominent gene candidate has been the polymorphisms in the renin–angiotensin–
aldosterone system [Singh, 2016].  It was noticed that all these 11 novel genetic variants of 
interest were relevant to either intronic or intergenic non-coding genes. Therefore, these variants 
potentially could influence hypertension’s pathogenesis by regulating relevant DNA transcription 
and translation. Regardless, our research points to future investigation direction in which the 
biological functions of these genetic variants and potential pathways leading to hypertension 
should be studied more to understand if and how reproductive genetic variants influence 
hypertension development.  
 
Strengths and limitations 
Our study has numerous strengths that can give credence to the observed association between 
reproductive timing related genetic variants and blood pressure, which suggested that these 
reproductive timing related genetic variants affect BP during adolescent period, and may be used 
to further explain BP variation. The study was based on prospective BP assessments with 
repeated measurements starting in childhood and repeated well into adolescence. With repeated 
measurement modeling in blood pressure, the weakness of a relative small sample size was offset 
by increased statistical power. Also the study was able to adjust for potential confounding factors 
of age, race, sex, and BMI. The study result can be given more credence because the observed 
association remained significant after adjusting for type 1 error using Bonferroni method, which 
is the most conservative statistical multiplicity adjustment. A unique strength of our study was 
that it gave us an opportunity to study the difference in ethnicity effect on blood pressure and 
enable us to demonstrate the interaction between ethnicity and genetic variants, which suggested 
the roles of these genetic variants varied across ethnicities in the process of BP development.  
Including AA subjects in the study provided valuable data that were usually not available in 
previous GWAS studies.  
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Even with this new idea of studying the effect of reproductive timing related genetic variants on 
blood pressure, this study is deemed to be exploratory, and will be limited to scientific 
assumption generation. Due to a relative small sample size, any discovery of this study will be 
subject to replication and validation in larger sample sized studies and different study populations 
with different racial backgrounds. On the other hand, lack of statistical significance for other 
genetic variants not found statistically significant in this study should not be interpreted as 
evidence for lack of association because of limited power in this study. This study as an 
observational study cannot rule out residual confounding completely.  To further understand the 
mechanism how any of these genetic variants play the role in the pathophysiology, it will be 
important to link any potential discoveries to existing or novel pathways that regulate 
hypertension. This could be achieved by implementing any or all of these in future studies: 
sequencing whole genomes, zooming in to deeply sequence target regions, studying the variants 
expressions, and study microbial diversity in humans or in the environment [Cabrera, 2015; 
Padmanabhan,2015; Munroe, 2013; Fontana 2015; Arwood,2015].  
 
Conclusion 
 
Genetic variants from previous GWAS that were originally found associated with women’s 
reproductive aging showed significant associations with BP in healthy male and female 
adolescents. The genetic effects were independent of a subject’s sex, race or growth related 
factors such as weight, height, and BMI. These significant variants were not reported in recently 
published SNPs association with BP. Thus they may represent novel candidates for BP genes, and 
give clues for discovering better ways for hypertension prevention and control. The findings need 
to be validated in different and large-scale populations, and the mechanism how reproductive 
related genes influence hypertension development needs to be studied.   
 14 
Table 1-1. Groups of SNPs associated with traits of age at menarche and age of menopause 
SNP 
Group 
SNP Locus Near Gene Function Major/Min
or Allele 
MAF Risk 
Allele
* 
Group A 
(n=16):  
associate
d with 
age at 
menarche 
rs466639 1q23.3 RXRG Intronic C/T 0.13 T 
rs1726878
5 
2p16.1 CCDC85A Intronic A/G 0.17 A 
rs7642134 3p12.1 VGLL3 Intergeni
c 
G/A 0.43 A 
rs6438424 3q13.32 LOC1004216
70 
Intergeni
c 
A/C 0.46 A 
rs1318728
9 
5q31.1 PHF15 Intergeni
c 
C/G 0.23 C 
rs1079866 7p14.1 INHBA Intergeni
c 
C/G 0.12 C 
rs7821178 8q21.11 PEX2  Intergeni
c 
C/A 0.42 A 
rs2090409 9q31.2 TMEM38B Intergeni
c 
C/A 0.39 A 
rs1098092
6 
9q31.3 ZNF483 Intronic G/A 0.40 G 
rs1089948
9 
11q14.1 GAB2 Intronic C/A 0.12 C 
rs6589964 11q24.1 BSX Intergeni
c 
C/A 0.48 A 
rs9635759 17q21.3
3 
CA10 Intergeni
c 
G/A 0.30 G 
rs1398217 18q21.1 SKOR2 Intronic C/G 0.40 G 
rs1042367
4 
19p13.1
1 
CRTC1 Intronic C/A 0.39 C 
Group B 
(n=8):  
associate
d with 
age at 
menarche 
and BMI 
rs2815752 1p31.1 NEGR1 Intergeni
c 
A/G 0.36 A, A 
rs1091346
9 
1q25.2 SEC16B Intronic T/C 0.25 C, C 
rs6548238 2p25.3 TMEM18 Intergeni
c 
C/T 0.15 C, C 
rs7647305 3q27.2 ETV5 Intergeni
c 
C/T 0.20 C, C 
rs1093839
7 
4p12 GNPDA2 Intergeni
c 
A/G 0.45 G, G 
rs987237 6p12.3 TFAP2B Intronic A/G 0.16 G, G 
rs7138803 12q13.1
2 
FAIM2 Intergeni
c 
G/A 0.35 A, A 
rs9939609 16q12.2 FTO Intronic T/A 0.46 A, A 
Group C 
(n=7): 
associate
d with 
age at 
rs6440003 3q23 ZBTB38 Intronic A/G 0.43 G,G 
rs1094680
8 
6p22.2 HIST1H1D Intergeni
c 
A/G 0.30 G, G 
rs7759938 6q16.3 LIN28B Intergeni
c 
T/C 0.36 T, C 
 15 
menarche 
and 
height 
rs4549631 6q22.32 LOC728666 Intergeni
c 
C/T 0.46 C, T 
rs1042725 12q14.3 HMGA2 Intergeni
c 
T/C 0.49 T, T 
rs1659127 16p13.1
2 
MKL2 Intergeni
c 
G/A 0.30 G, G 
rs4794665 17q22 NOG Intergeni
c 
G/A 0.46 A, G 
rs757608 17q23.2 TBX2 Intergeni
c 
G/A 0.31 A, G 
rs4800148 18q11.2 CABLES1 Intronic A/G 0.24 A, G 
Group D 
(n=15): 
associate
d with 
age at 
menopaus
e 
rs1018348
6 
2q13.1 TLK1 intronic C/T 0.37 T 
rs1046089 6p21.33 BAT2 missense G/A 0.35 A 
rs1085234
4 
16p13.1
3 
--   T/C 0.42 T 
rs1166834
4 
19q13.4
2 
TMEM150B intronic A/G 0.36 G 
rs1246111
0 
19q13.4
3 
NLRP11 missense G/A 0.36 A 
rs1635501 1q43 EXO1 intronic T/C 0.48 T 
rs1699161
5 
20p12.3 MCM8 missense G/A 0.07 G 
rs2153157 6p24.4 SYCP2L intronic G/A 0.49 G 
rs2277339 12q13.3 PRIM1 missense T/G 0.10 T 
rs2303369 2p23.3 FNDC4 intronic C/T 0.39 T 
rs2307449 15q26.1 POLG intronic T/G 0.41 G 
rs2517388 8p11.23 ASH2L intronic T/G 0.17 T 
rs4246511 1p34.3 RHBDL2 intronic C/T 0.27 T 
rs4693089 4q21.23 HELQ intronic A/G 0.49 G 
rs4886238 13q21.2 TDRD3 intronic G/A 0.33 G 
SNP: single nucleotide polymorphisms  
MAF: major allele frequency 
* Risk allele refers to the allele that was associated with a younger age at menarche or at natural 
menopause in previous GWAS [Elks, 2010; Stolk, 2012]   
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Table 1-2.  Characteristics of study subjects 
 Boys Girls 
 Whites 
(n=170) 
Blacks 
(n=112) 
P value Whites 
(n=168) 
Blacks 
(n=151) 
P value 
 Mean ± SD  Mean ± SD  
Study Entry       
Age(yr) 10.2 ± 0.3 12.1 ± 0.3 0.0001 10.8 ± 0.3 12.5 ± 0.3 0.0001 
BMI (kg/m2) 19.0 ± 0.4 21.9 ± 0.6 0.0001 18.9 ± 0.3 22.8 ± 0.6 0.0001 
Weight(kg) 40.6 ± 1.7 53.1 ± 2.3 0.0001 39.9 ± 1.3 54.3 ± 2.0 0.0001 
Height(cm) 141.3 ± 1.5 152.1 ± 1.8 0.0001 141.9 ± 1.3 150.8 ± 1.3 0.0001 
SBP (mmHg) 100.7 ± 
12.1 
104.1 ± 
11.9 NS 98.6 ± 11.3 
103.0 ± 
10.8 0.002 
DBP 
(mmHg) 60.4 ± 10.5 61.9 ± 10.2 NS 60.5 ± 10.2 63.3 ± 9.5 NS 
Follow-up 
period 
      
Number of 
visits 12.9 ± 0.6 8.8 ± 6.1 0.0001 12.0 ± 0.5 8.4 ± 0.5 0.0001 
Age (yr) 13.6 ± 0.1 14.3 ± 0.2 0.003 13.9 ± 0.1 14.4 ± 0.2 0.02 
BMI (kg/m2) 21.6 ± 0.4 23.9 ± 0.5 0.0004 21.4 ± 0.4 25.2 ± 0.4 0.0001 
Weight 
(kg/m2) 57.7 ± 1.3 65.7 ± 1.6 0.0002 52.9 ± 1.3 64.1 ± 1.4 0.0001 
Height (cm) 160.4 ± 0.8 163.9 ± 1.0 0.006 155.5 ± 0.7 157.8 ± 0.8 0.03 
SBP (mmHg) 106.7 ± 
12.7 
108.7 ± 
12.2 NS 
102.4 ± 
10.1 
105.4 ± 
10.4 0.002 
DBP 
(mmHg) 61.9 ± 10.9 63.9 ± 10.8 NS 61.7 ± 9.9 63.1 ± 10.0 0.05 
SD: standard deviation; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic 
blood pressure. 
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Table 1-3. Significant SNP associations with BP 
SNP Groupa Genetic 
Model 
Effect 
allelee 
 
BP Outcome P-value P-hetb P-hetc 
DBP 
rs10423674 BM dominant C more DBP 
increase (slope) 
0.001 0.03 0.003 
SBP 
rs1079866 WF additive C more SBP 
increase (slope) 
0.003 NS 0.002 
rs13187289 BM recessive C higher SBP 
(shift) 
0.001 0.005 0.08 
rs17268785d BF dominant A less SBP 
increase (slope) 
0.001 0.008 0.03 
rs7642134d BF dominant A less SBP 
increase (slope) 
0.003 0.02 NS 
rs9635759 BM recessive G more SBP 
increase (slope) 
0.002 0.02 0.01 
rs7647305 W additive C more SBP 
increase (slope) 
0.003 0.01 NS/NS 
rs10946808d 
 
WM dominant G lower SBP 
(shift) 
0.005 0.02 0.001 
rs6440003 
 
WF additive G more SBP 
increase (slope) 
0.003 0.03 0.007 
rs757608d BM dominant A 
 
less SBP 
increase (slope) 
0.004 0.03 NS 
rs2153157 
 
W recessive G more SBP 
increase (slope) 
0.003 0.04 0.02 
SBP: systolic blood pressure; DBP: diastolic blood pressure a BF, Black Females; BM, Black 
Males; WF, White Females; WM, White Males; B, Blacks; W, Whites. 
b p-value for heterogeneity for racial difference 
c p-value for heterogeneity for sex difference 
d the SNP association with BP is not in the direction predicted by its association with age at 
menarche or menopause  
e Effect allele refers to the risk allele in the table 1-1 
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Study 2: Discovery Bivariate Meta-analysis of GWAS on Blood Pressure and Age at 
Menarche/ Natural Menopause 
 
 
Introduction 
 
It was well established that increased blood pressure (BP) increases risk of cardiovascular 
diseases such as myocardial infarction and stroke, chronic renal disease, premature death and 
disability. Hypertension is the one of the leading causes of death in the US. The total costs of 
health care services, medications to treat high blood pressure, and missed days of work due to 
hypertension are about $48.6 billion each year [CDC blood pressure fact sheet, 2016].   Multiple 
environment, lifestyle, and genetic factors contribute to hypertension.  The environment and 
lifestyle factors include obesity, excessive salt intake, less potassium intake, excessive alcohol 
intake, and insufficient physical activity and stress [Remington 2010]. Genetically, the heritability 
of BP has been estimated to be 30–50% [Munroe, 2013]. The accumulated data suggest that 
blood pressure regulation in general is likely to be influenced by multiple genetic variants, and 
the most prominent gene candidate that has been identified so far is relevant to the 
polymorphisms in the renin–angiotensin–aldosterone system [Sigh, 2016].  However, the 
identified genetic variants from GWAS together only explain less than 3% of the total variance of 
BP and many of genetic variants that can explain inheritability have been missed in the GWAS 
studies [Munroe, 2013].  
 
Reproductive timing, age at menarche (AAM) as well as age at natural menopause (AANM), are 
found associated with increased BP and risk of cardiovascular diseases [Lakshman, 2009; Hu 
1999]. BP measures, both systolic and diastolic BP, increase at an accelerated rate with onset of 
sexual maturation [Shankar 2005]. Early menarche is associated with elevated BP in adolescent 
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and adulthood [Koziel 2001; Dianels1998].  BP is also known to increase more steeply around 
age at menopause [Lindquist 1982]. Earlier menopause is associated with higher BP [Staessen, 
1989; Izumi, 2007], although it is still unclear whether menopause accelerates BP increase or 
increased BP leads to earlier menopause. The observed synchronization between reproductive 
aging and BP increase raises questions about the possibility of common regulating mechanisms 
shared by these processes.   
 
Previous GWAS studied the associations between common genetic variants, and AAM, AANM 
and BP, separately (Elks 2010, Stolk 2012 and Ehret 2011).  However, no study was conducted to 
explore if common genetic variants, with pleiotropic effects, are associated with both traits BP 
and reproductive timing.  Therefore, we conducted a bivariate analysis to evaluation association 
between the traits (i.e., BP and reproductive timing) and the common genetic variants from 
previous GWAS.  
 
Materials and Methods 
 
GWAS data sources 
Full details of the individual GWAS were given in the original publications [Perry 2014, Ehret 
2011, Elks 2010, Stolk, 2012], but briefly, the BP GWAS included 29 studies, comprising 69,395 
individuals the menarche GWAS included 32 studies, comprising 87 802 women; and the 
menopause GWAS included 22 studies, comprising 38 968 women. All subjects were of white 
European ancestry. Blood pressure was measured directly in the BP GWAS subjects.  The ages at 
menarche (AAM), ranging from 9-17 years as recalled by the women in the menarche GWAS, 
were included in the analysis.   Age at natural menopause (AANM) was defined as the age at the 
last menstrual period that occurred naturally. Those AANMs, ranging from 40 to 60 years as 
reported by the women in menopause GWAS, were included in the analysis. The woman subjects 
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were excluded if their menopause was due to hysterectomy and/or bilateral ovariectomy, or 
chemotherapy/irradiation, or if they received hormone replacement therapy before menopause as 
ascertained by medical records.   
 
The study subjects were genotyped using a variety of Affymetrix (6.0, GeneChip 500K, 250K, 
MIP50K and 10K) and Illumina (HumanHap 550K, 318K, 370 K, HumanHap 300K, HumanHap 
370K CNV, HumanHap610 quad, Human660W-Quad BeadChip, 6K and Human 1Mv1_C, 
HumanHap300 Duo "+") genotyping arrays. For the unmeasured SNPs, genotypes were imputed 
in these studies. Altogether, 2.5 million genotyped or imputed single nucleotide polymorphisms 
(SNPs) were included in the GWAS meta-analyses [Perry 2014, Ehret 2011, Elks 2010, Stolk, 
2012].  
 
Written informed consent was provided by all participants and the studies were approved by local 
Research Ethics Committees and/or Institutional Review Boards.    
 
Statistical analysis 
Overall, the associations between the SNPs and the trait pairs of BP and reproductive timing were 
explored by using a multivariate analysis approach, which is similar with other multivariate 
approaches for potential pleiotropic effects. We essentially tested the null hypothesis (H0) that the 
parameter estimate for genetic effect was 0 for both traits (e.g., β1 = 0 for SBP and β2 =0 for 
AAM).  The goal of this bivariate approach was to identify more GWAS loci with potential 
pleiotropic effects when two correlated traits together were combined. However, the SNPs with 
significant bivariate GWAS p-values were not necessary to be pleiotropic SNPs because there 
were 3 potential alternative hypotheses (H1) (β1≠0 and β2 ≠ 0; β1=0 and β2 ≠ 0; β1≠0 and β2= 0). 
To accommodate these multiple alternative H1, we compared the p-values from bivariate GWAS 
with the p-values from univariate GWAS. When a SNP with a potential pleiotropic effect, its 
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bivariate GWAS p-value should be smaller than its univariate GWAS from each of the 
phenotypes. A rule was set up to consider a SNP with potential pleiotropic effect if its bivariate 
GWAS p-value was one order of magnitude smaller than the p-values from both univariate 
GWAS.   The simulation suggested that this screening process is able to capture the most but not 
all of SNPs with pleiotropic effects and reduce the false positive rates for those SNPs without 
pleiotropic effects [Personal correspondence with Dr. Yi-Hsiang Hsu].  In this bivariate analysis, 
empirical-weighted linear-combined test statistics (eLC), as proposed by Dr. Hsu [Perry 2014], 
directly combined correlated test statistics that were obtained from univariate GWAS meta-
analyses, with a weighted sum of univariate test statistics to maximize the overall association 
signals and accounted for the correlation between phenotypes. An optimal weighting was 
estimated empirically, so that the smallest variance of the combined test statistics among all the 
possible combinations was used for the new test statistics. An empirical permutation test was then 
used to estimate p-values for the eLC new test statistics. Bivariate P-values <5 × 10-8 for the 
SNPs were considered genome-wide significant with potential pleiotropic effects.  Bivariate P-
values <1 × 10-5for the SNPs were also reported in the discovery bivariate analyses.  
 
The data used in the discovery bivariate analyses were aggregated from univariate GWAS meta-
analyses that were conducted for the 2.5 million SNPs in BP consortium and ReproGen 
consortium.  Detailed statistics method on univariate GWAS meta-analyses was described in the 
published literature [Perry 2014, Ehret 2011, Elks 2010, Stolk, 2012], but briefly, linear 
regression under additive genetic modelling estimated statistics (regression effect betas, standard 
errors and P values) for the associations between SNPs and each of the individual traits such as 
BP, and reproductive timing trait (AAM or AANM), separately. These univariate analyses were 
conducted for each of 2.5 million genotype or imputed SNPs, and thus generated the aggregated 
data for the discovery bivariate analyses, in which 4 pairs of traits of interest were studied: 
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diastolic blood pressure (DBP) and AAM; DBP and AANM; systolic blood pressure (SBP) and 
AAM; and SBP and AANM.  
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Results 
 
At genome-wide significance level (P< 5X10-8), the bivariate analyses on the aggregated data 
showed that 49 SNPs were associated with the trait pair SBP_AAM, 25 SNPs were associated 
with the pair SBP_AAM; 65 SNPs with the pair DBP_AANM; and 28 SNPs with the pair 
SBP_AANM (Table 2-1).  No matter it was DBP or SBP, 22 SNPs of the above significant SNPs 
(P < 5X10-8) were consistently associated with both pairs DBP_AAM, and SDP_ AAM; and 17 
SNPs with both pairs DBP_AANM, and SDP_AANM (Table 2-2).   
 
At genome-wide significance level (P< 1X10-5), the bivariate analyses suggested many more 
SNPs associated with the trait pairs: 525 SNPs were associated with the trait pair SBP_AAM, 508 
SNPs were associated with the pair SBP_AAM; 591 SNPs with the pair DBP_AANM; and 437 
SNPs with the pair SBP_AANM.  No matter it was DBP or SBP, 192 SNPs of the above 
significant SNPs (P < 5X10-5) were consistently associated with both pairs DBP_AAM, and 
SDP_ AAM; and 212 SNPs with both pairs DBP_AANM, and SDP_AANM.  
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Discussion 
 
In this analysis, we identified more than one hundred SNPs were associated with both traits of 
reproductive timing and BP.  It suggested that those genetic variants that were previously 
associated with reproductive timing, and associated with BP, separately, could have potential 
pleiotropic effects on both traits. Identifying the novel genetic variants that explain BP more is 
important because it may bring about the clues for developing better solutions for hypertension 
prevention and control. Our bivariate analysis approach leading to these findings may help 
identifying more novel variants associated with BP. 
 
Epidemiological data on phenotypes suggests that [Lakshman, 2009; Hu 1999; Shankar, 2005; 
Koziel, 2001; Dianels,1998; Lindquist, 1982; Staessen, 1989; Izumi, 2007] both factors of age at 
menarche and age at natural menopause are associated with the risk of cardiovascular disease as 
well as its risk factors including blood pressure (BP). The observed synchronization between 
reproductive timing and hypertension development raises questions about the possibility of 
common pathophysiology process involving both reproductive timing and hypertension 
development. To date, no study has directly addressed the association between common genetic 
variation related to both reproductive timing and BP development [Zhang, 2013, Johnson, 2015, 
Ehret 2011, Spencer 2013].  However, understanding more about the association between these 
genetic variants and BP development is important for the following reasons.  First, more genes 
that can contribute to blood pressure variation remain to be discovered. The heritability of BP has 
been estimated to be 30–50%, but the genetic variants identified through GWAS together explain 
less than 3% of the total variance of BP. Thus, many of the genetic variants that can explain 
heritability have been missed in the GWAS studies [Munroe, 2013].  Second, any seemly trivial 
novel gene discovery, even with a small magnitude of association, could have utility for disease 
prevention and clinical management. Observational data suggests that a slight increase in BP can 
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execute a great impact on health outcome: an increase in SBP by 2 mm Hg increases stroke risk 
by 10% and coronary risk by 7% (Lewington, 2002).  Therefore, any novel genes associated with 
blood pressure that does not seem impressive at first discovery could have great impact on 
identifying high risk population for implementing prevention in early life before full-blown 
presentations of clinical BP and its complications or can be applied in anti-hypertensive 
medication development. In an analog example, widely used anti-diabetic medication class 
glitazones has been developed based on original finding on the gene product of PPARG, a gene 
with an odds ratio only about 1.2 for association with type 2 diabetes mellitus [Lohmueller, 
2002]. 
 
In this study, we hypothesized that some common genetic variants have pleiotropic effects both 
on BP and reproductive timing.  This hypothesis is supported by recent meta-analysis of GWAS 
in which genetic variants were associated with both age at menopause and serum urate [Zhang, 
2013], a trait correlated with blood pressure [Johnson, 2015].  In addition, genetic variant intronic 
ARHGAP42 rs633185 was reported associated with a blood pressure in a GWAS study [Ehret 
2011], and was also associated with age at menarche and age at natural menopause in another 
meta-analysis of GWAS [Spencer 2013].  By using the eLC approach, we speculate that we will 
be able to discover more common genetic variants that could be associated with both BP and 
reproductive timing because eLC approach has the following advantages: (1) eLC does not 
require individual level genotype and phenotype information, so it can be conveniently applied to 
re-analyze the aggregated data from univariate meta-analysis on existing GWAS; (2) eLC avoids 
the loss of statistical power due to missing data for one of the studied phenotypes [Perry 2014].  
At genome-wide significance level (P< 5X10-8), our bivariate analyses demonstrated that more 
than one hundred SNPs were associated with both traits of BP and reproductive timing. It turned 
out that some of the significant SNPs (e.g., rs1046089, rs1077393, rs11748651, rs2736176, 
rs2763979, rs2844477, rs3751813, rs707929, and rs805294) from this bivariate analysis had not 
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been found associated with BP in the previous GWAS meta-analyses [PhenoScanner 2017]. 
Therefore, our study suggested some of these SNPs could become novel genes that are 
contributable to blood pressure regulation.  
 
Although, eLC, as a screening tool, was able to screen more than one hundred SNPS both 
associated with BP and reproductive timing, this bivariate GWAS meta-analysis should be 
considered preliminary at a discovery stage like other GWAS aiming to discover novel genes 
associated with a phenotype or phenotypes. Our findings are subject to validation in larger sample 
sized studies and different study populations with different racial backgrounds. For validation, we 
propose that we use two criteria to define SNPs with potential pleiotropic effects: (1) bivariate p 
values < 5x10-8 from the eLC test and (2) p-values from bivariate analysis must be smaller than 
the p-values from each univariate analyses. We also propose to prioritize SNPs for replication 
that meet this criterion based on functional relevance and importance to trait biology (see 
discussion on biological mechanisms).  The validation would require individual level data from 
additional studies that ideally do not contribute to our preliminary results.  Again, Bonferroni 
correction will be used to account for multiple testing.  Because of the limited statistical power 
inherently in the GWAS, lack of statistical significance for other genetic variants not found 
genome-wide significant (P< 5X10-8) should not be interpreted as evidence for lack of 
association. At a liberal genome-wide significance level (P< X10-5), more than one thousand 
SNPs were found associated with both traits of BP and reproductive timing. Therefore, more 
SNPs can be considered at the validation stages.  In addition to the bivariate analyses, tri-variate 
analyses (e.g., association between an SNP and trivariates menarche, SBP and DBP) or even qua-
variate analyses may be explored to enhance statistical power to discover more common genetic 
variant candidates for validation.   
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To date, the variance of BP explained by the genetic variants has remained small (~3%), and how 
the genetic variants play the role in the pathophysiology of developing hypertension has remained 
largely unknown [Munroe, 2013].  It is important to link any potential discoveries to existing or 
novel pathways that regulate hypertension in the process of discovering attributable novel genes.  
A brief functional review on the genes near the discovered genome-wide significant SNPs (P< 
5X10-8) revealed that the gene DDAH2 encodes a dimethylarginine dimethylaminohydrolase. 
This encoded enzyme functions in generation of nitric oxide (NO), which is known to be involved 
in BP regulation.  NO affects the cardiac changes and endothelium vasodilation [NCBI gene 
website 2017].  However, it is hard to directly map most of the discovered genes to the well-
established pathways for BP including renin-angiotension-aldeosterone system, kallikrein-kinn 
system, ion channels, transporters, natriuretic proteins, nitric oxide, and endolthelin systems 
[Cabrera 2015].  Even so, we noticed that numerous genes are associated with the common 
diseases/conditions coexisting with hypertension. For example, the gene ARNTL was found 
associated with problems with gluconeogenesis and lipogenesis, and altered sleep pattern; DLK1 
with adult and adolescent obesity; and FTO with obesity and type 2 diabetes.  Although it is 
challenging to distinguish between the causal mechanisms specifically related to hypertension 
and those linked to other diseases/conditions, it is biologically plausible that these genes could 
have direct or indirect effect on BP because BP is likely determined by many susceptibility genes, 
each of which has a small effect size. As mentioned above these discovered genes need validation 
in future studies.   Meanwhile, other genes such as RXRG, DCAKD, BSX, RP34P23, LY6G6C, 
PRRC2A, BAG6, BCL2, VWA7, NRG1, and ULK4 appeared limited in evidence that supports 
an association with BP based on the current knowledge of hypertension etiology and 
pathophysiology. These findings could be either from false-positive results or implied that, if 
there were true effects, they could be involved in the novel pathways for BP.  To understand more 
about the biological mechanisms for any novel genes., future studies can be implemented to focus 
on sequencing whole genomes, zooming in to deeply sequence target regions, studying the 
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variants expressions, and study microbial diversity in humans or in the environment [Cabrera, 
2015; Padmanabhan,2015; Munroe, 2013; Fontana 2015; Arwood,2015].  We wish that these 
GWAS and biological mechanism studies help identify new drug targets, and give clues to help 
hypertension prevention and clinical management.   
 
Conclusion 
 
Our preliminary discovery bivariate analysis results suggested that more than a hundred of SNPs 
may have potential pleiotropic effects both on BP and reproductive timing. Our approach of 
bivariate GWAS meta-analysis may help identify more genetic variants attributable to BP that 
will be eventually used for searching more effective prevention and management of hypertension.   
However, the SNPS identified in our analysis will be subject to validation in different study 
samples with individual-level data that do not contribute to our observations, and in biological 
mechanism studies.    
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 Table 2-1. Genome-wide significant SNPs (P< 5 X 10-8) by trait pair in discovery bivariate analyses  
Trait pair   SNP Locus  Position Near Gene  P  Note 
DBP 
_AAM  
    DBP_AAM* AAM only# DBP only# 49 significant 
SNPs^   
 rs900145 11p15.2 13250481 ARNTL 1.39E-10 7.66E-09 0.000873 33 other 
SNPs in high 
LD 
 rs285482 1 163677347 RXRG 5.36E-10 9.81E-10 0.00703  
 rs16948048 17q21.32 44795465 ZNF652 1.44E-09 0.0001717 1.38E-06 2 other SNPs 
in high LD 
 rs1190903 14q32.2 100166167 Intergenic 
between 
BEGAIN and 
DLK1 
3.39E-09 9.56E-07 0.000489 3 other SNPs 
in high LD 
 rs3751813 16q12.2 52376209 FTO 5.81E-09 7.75E-08 0.00388  
 rs4905976 14 100130358 Intergenic 
between 
BEGAIN and 
DLK1 
1.55E-08 1.60E-08 0.0176 5 other SNPs 
in high LD 
SBP 
_AAM 
    SBP_ AAM* AAM only# SBP only# 25 significant 
SNPs^   
 rs285482 1 163677347 RXRG 7.64E-10 0.00886 9.81E-10  
 rs900145 11 13250481 ARNTL 1.10E-09 0.00408 7.66E-09 19 other 
SNPs in high 
LD 
 rs2194899 1 163677409 RXRG 5.62E-09 0.0112 9.85E-09  
 rs4793172 17q21.31 40487006 DCAKD 2.39E-08 1.11E-06 0.002302  
 rs7111924 11 122371312 Intergenic 
between BSX 
and RPL34P23 
4.34E-08 0.019 5.78E-08  
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 rs1190903 14q32.2 100166167 Intergenic 
between 
BEGAIN and 
DLK1 
4.51E-08 0.00422 9.56E-07  
DBP_ 
AANM   
    DBP_AANM* AANM 
only# 
DBP only#  65 significant 
SNPs ^ 
 rs1046089 6 31710946 PRRC2A 7.59E-14 0.00119 1.31E-13 5 other SNPs 
in high LD 
 rs805294 6 31796196 LY6G6C 7.26E-11 4.31E-05 2.14E-07 4 other SNPs 
in high LD 
 rs805305 6 31805366 DDAH2 5.20E-10 9.64E-05 7.55E-07  
 rs2763979 6 31902571 Intergenic 
between 
HSPA1A and 
HSPA1B 
6.54E-10 6.95E-05 1.46E-06  
 rs2736155 6 31713178 PRRC2A 1.55E-09 0.000563 2.62E-07  
 rs1077393 6 31718508 BAG6 1.64E-09 0.000562 2.79E-07  
 rs707929 6 31850046 VWA7 4.22E-09 0.000469 1.13E-06  
 rs2471980 6 31908847 C6orf48 7.01E-09 0.00071 1.18E-06  
 rs776387 8 31857593 NRG1 2.41E-08 0.000838 4.14E-06 2 other SNPs 
in high LD 
 rs9856088 3 41835486 ULK4 2.93E-08 1.90E-07 0.007213 45 other 
SNPs in high 
LD 
SBP_ 
AANM   
    SBP_ AANM* AANM 
only# 
SBP only#  28 significant 
SNPs ^ 
 rs2242660 6 31705732 PRRC2A 6.70E-15 1.30E-06 3.94E-10 5 other SNPs 
in high LD 
 rs2736155 6 31713178 PRRC2A 3.90E-12 2.17E-06 2.62E-07  
 rs1077393 6 31718508 BAG6 4.25E-12 2.22E-06 2.79E-07  
 rs805294 6 31796196 LY6G6C 5.75E-11 3.42E-05 2.14E-07 4 other SNPs 
in high LD 
 rs805305 6 31805366 DDAH2 1.08E-10 2.15E-05 7.55E-07  
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 rs2763979 6 31902571 Intergenic 
between 
HSPA1A and 
HSPA1B 
5.07E-10 5.38E-05 1.46E-06  
 rs2471980 6 31908847 Intergenic 
between 
HSPA1B and 
C6orf48 
7.76E-10 9.61E-05 1.18E-06  
 rs707929 6 31850046 VWA7 2.03E-09 0.000241 1.13E-06  
 rs2844477 6 31686751 Intergenic 
between NCR3 
and 
UQCRHP1 
2.66E-08 0.00939 1.00E-07 4 other SNPs 
in high LD 
 rs11748651 5 171864544 Intergenic 
between 
SH3PXD2B 
and NEURL1B 
2.88E-08 0.0111 8.15E-08 1 other SNP 
in high LD 
 rs781427 4 84762727 Intergenic 
between 
AGPAT9 and 
NKX6-1 
3.30E-08 0.0133 6.89E-08  
 rs7029 6 31737932 GPANK1 4.31E-08 0.000374 2.19E-05 1 other SNP 
in high LD 
 rs2736176 6 31695540 Intergenic 
between AIF1 
and PRRC2A 
4.44E-08 0.0202 4.44E-08  
*P value from bivariate analysis  
#P value from univariate GWAS meta-analysis 
^ genome-wide significance level < 5 X 10-8 
AAM: age at menarche 
AANM: age at natural menopause;  
DBP: diastolic blood pressure 
DBP_AAM: trait pair of diastolic blood pressure and age at menarche 
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DBP_AANM: trait pair of diastolic blood pressure and age at natural menopause 
High LD: high linkage disequilibrium (R2>0.8)  
SBP: systolic blood pressure 
SBP_AAM: trait pair of systolic blood pressure and age at menarche 
SBP_AANM: trait pair of systolic blood pressure and age at natural menopause 
SNP: single nucleotide polymorphisms 
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Table 2-2. Summary of SNPs (P< 5 X 10-8) that were consistently genome-wide significant^ for trait blood pressure and reproductive aging 
regardless of it was SBP or DBP* 
Trait pairs   SNP Locus  Position Near 
Gene 
 P value  Note 
DBP_AAM 
and 
SBP_AAM 
    SBP_AAM* DBP_AAM* AAM 
# 
SBP # DBP # 22 
significant 
SNPs ^  
 
rs285482 1 163677347 RXRG 7.64E-10 5.36E-10 
9.81E-
10 0.00886 0.00703  
 
rs900145 11p15.2 13250481 ARNTL 1.10E-09 1.39E-10 
7.66E-
09 0.00408 0.000873 
12 other 
SNPs in 
high LD 
 
rs6486120 11p15.2 13280718 ARNTL 5.68E-09 4.52E-10 
2.37E-
08 0.00726 0.0011 
6 other 
SNPs in 
high LD 
 
rs1190903 14q32.2 100166167 
Intergenic 
between 
BEGAIN 
and 
DLK1 4.51E-08 3.39E-09 
9.56E-
07 0.00422 0.000489  
DBP_AANM 
and 
SBP_AAM 
    SBP_AAM* DBP_AAM* AAM 
# 
SBP# DBP# 17 
significant 
SNPs ^  
 rs1046089 6 31710946 PRRC2A 6.99E-16 7.59E-14 
1.31E-
13 4.30E-05 0.00119 
5 Other 
SNPs in 
high LD 
 rs2736155 6 31713178 PRRC2A 3.90E-12 1.55E-09 
2.62E-
07 2.17E-06 0.000563  
 rs1077393 6 31718508 BAG6 4.25E-12 1.64E-09 
2.79E-
07 2.22E-06 0.000562  
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 rs707916 6 31805537 DDAH2 9.69E-11 1.14E-10 
2.98E-
07 4.25E-05 5.03E-05 
4 Other 
SNPs in 
high LD 
 rs805305 6 31805366 DDAH2 1.08E-10 5.20E-10 
7.55E-
07 2.15E-05 9.64E-05  
 rs2763979 6 31902571 
Intergenic 
between 
HSPA1A 
and 
HSPA1B 5.07E-10 6.54E-10 
1.46E-
06 5.38E-05 6.95E-05  
 rs2471980 6 31908847 
Intergenic 
between 
HSPA1B 
and 
C6orf48 7.76E-10 7.01E-09 
1.18E-
06 9.61E-05 0.00071  
 rs707929 6 31850046 VWA7 2.03E-09 4.22E-09 
1.13E-
06 0.000241 0.000469  
* P values for SNPs that were consistently genome-wide significant (P<5X10-8) for both trait pairs of DBP_AAM and SBP_AAM, or both trait 
pairs of DBP_AANM and SBP_AANM in bivariate analyses.  
#P value from univariate GWAS meta-analysis 
^ Genome-wide significance level < 5 X 10-8. No matter it was DBP or SBP, 22 were consistently associated with both pairs DBP_AAM, and 
SDP_ AAM; and 17 SNPs with both pairs DBP_AANM, and SDP_AANM.   
AAM: age at menarche 
AANM: age at natural menopause;  
DBP: diastolic blood pressure 
DBP_AAM: trait pair of diastolic blood pressure and age at menarche 
DBP_AANM: trait pair of diastolic blood pressure and age at natural menopause 
High LD: high linkage disequilibrium (R2>0.8) 
SBP: systolic blood pressure 
SBP_AAM: trait pair of systolic blood pressure and age at menarche 
SBP_AANM: trait pair of systolic blood pressure and age at natural menopause 
SNP: single nucleotide polymorphisms
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Study 3: Menarche Related Genetic Variants from Genome-Wide Association Studies Are 
Associated with Height Growth Catchup in Healthy Adolescents 
 
 
Introduction 
 
Parents may be concerned or anxious about the short stature of their short children (Woolford 
2007). Adolescents undergo rapid changes in linear body growth as well as psychological and 
social functions (Nelson, 2016).  Accelerated growth among adolescents usually starts from first 
visible sign of puberty when testicular enlargement in boys and appearance of breast buds 
(thelarche) in girls until an adult height is achieved (Nelson, 2016). However, the timing of 
growth acceleration varies widely (Nelson, 2016), and those children who appear short may be 
experiencing constitutional growth delay and will catch up later in the adolescence period 
(Kappy, 2010).  Other children could be constantly short during adolescence, and be adversely 
affected in psychological and social function development.  Short children could have 
maladaptive behaviors and emotional problems because of teasing and low self-esteem (Tanaka, 
2009; Ross, 2004).  Unproven or controversial treatments (Kappy, 2010, Ali 2011) could have 
been implemented on the children who appear short. Importantly, expensive treatments including 
growth hormone could impose financial burden on the treated children, their families, and our 
health care system (Kelnar, 1999).  Identifying those adolescents who appear short from 
adolescence and will continue to be short in adulthood is important for efficient and efficacious 
clinical consultation and management.   
 
Final adult height is determined by a complex combination of genetic and environment factors, 
but mainly by genetics which explains 60%-90% of height variation (Macgregor 2006; Roberts 
1978; Silventoinen 2003).  A meta-analysis published in 2014 (Wood 2014) included more than 
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250,000 individuals with European ancestry and revealed 697 common single nucleotide 
polymorphisms (SNPs) clustered in 423 different loci across the human genome that influence 
adult height.  These loci are enriched for genes that are connected in biological pathways and 
trigger skeletal growth defects, and explained approximately 16% of the height variation. The 
genome-wide association studies (GWASs) suggested future genetics epidemiology studies could 
explain more variance of height.  Other GWASs identified 31 genetic variants that were 
associated with age at menarche in women of European ancestry (Elks, 2010). Some of these 
SNPs were also associated with adult height and BMI (Elks, 2010).  But the effects of these 
genetic variations on height growth catchup failure (HGCF) among adolescents have not been 
investigated.  We hypothesize that common genetic variants have pleiotropic effects on age at 
menarche and HGCF.  Therefore, we conducted a study to evaluate association between HGCF 
and SNPs previously identified from GWAS that were associated with age at menarche in healthy 
adolescents. 
 
Patients and Methods 
 
Study population 
The study subjects were from a longstanding prospective cohort established in 1986 to study 
blood pressure development in children and adolescents. The detailed study design and data 
collection process have been described elsewhere [Pratt, 1989; Tu, 2011, Tu 2015].  Briefly, 
healthy children, aged 4-17 years were enrolled from 33 schools in Indianapolis, IN. Their 
participation was voluntary. Informed consent was obtained from each child as well as from his 
or her parents or a legal guardian. The study was approved by the institutional review board of 
Indiana University-Purdue University of Indianapolis. Self-reported race categories were 
recorded and validated [Tu 2009; T2014]. Children were excluded from the study if they had a 
history of renal or cardiac disease or diabetes mellitus [Pratt, 1989; Manatunga, 1993; Tu, 2011].  
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Body height and weight assessment  
Semiannual assessment of body height (cm) was conducted. Standing height measurements were 
carried out by using a stadiometer at enrollment and semiannually at the subject's school, in some 
instances in the Indiana University Clinical Research Center, or in the subject's home.  
Semiannual assessment of growth in weight was also conducted in these subjects [Manatunga, 
1993; Tu 2011]. BMI, defined as weight (kilograms)/height (meters)2 was calculated for each 
follow-up visit.  
 
We identified subjects who had body height at puberty onset (BHAPO) as well as body height at 
adult age (BHAAA). BHAPO was estimated at the age where first vital sign of puberty onset 
appears (i.e., when testicular enlargement appears in boys and breast buds (thelarche) appear in 
girls).  Because no sexual maturity rating or Tanner stage data were collected in the original 
cohort, we cannot directly observe puberty onset age in order to obtain a body height directly 
relevant to the puberty onset age. We, instead, estimated the BHAPO by using the body height 
observed close to the mean puberty onset age (i.e., 11.5 years for white boys, 10.5 years for black 
boys, 10.5 for white girls and 9.5 years for black girls) (Kappy, 2010).  We specifically used the 
periods one year before to one year after the mean puberty onset age by sex and race (10.5 – 12.5 
years for white boys, 9.5 – 11.5 years for black boys, 9.5 – 11.5 years for white girls, and 8.5 – 
10.5 years for black girls, respectively). Puberty onset weights within these periods were also 
measured. BHAAA were estimated by using the body height that was lastly observed after age 16 
for girls and after age 18 for boys when an adult body height is likely to have achieved (CDC 
growth chart; Benabbad, 2016). Center of Disease Control Growth Charts 2000 were used to give 
percentiles for the body heights measured (CDC growth chart).     
 
Blood samples, genotyping and SNP selection 
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DNA was extracted for participants with blood samples stored at -20° C.  Genotypes of the 
candidate SNPs were determined using the Sequenom MassArray iPLEX Platform (Sequenom, 
San Diego, CA). The genotyping success rate for each SNP was over 95% [Tu 2015]. Samples 
with missing genotypes higher than 2% were removed from the study. In the retained samples, all 
SNPs were in Hardy–Weinberg equilibrium (P value > 0.05). The allele frequency for each SNP 
in our data was consistent with that reported for populations of European and African descent in 
the International HapMap Project (http://hapmap.ncbi.nlm.nih.gov/).  We selected 31 independent 
SNPs that have been reported to be associated with age at menarche in the meta-analyses of 
GWAS of women of European ancestry [Elks, 2010]. These SNPs were either strongly associated 
with age at menarche (with reported p-value ≤ 1×10−8), or associated with both age at menarche 
and another adult growth outcome (height or BMI).  Based on their associations with age at 
menarche and other correlated growth traits, we categorized these SNPs into 3 groups: Group A 
included 16 SNPs associated with age at menarche only [Elks, 2010]; Group B included 8 SNPs 
associated with both age at menarche and adult BMI [Elks, 2010]; Group C included 7 SNPs 
associated with both age at menarche and adult height [Elks, 2010]. Detailed descriptions of the 
SNPs are listed in Table 3-1.  
 
Data Analysis 
Patient characteristics were summarized using sample mean and standard deviation (SD) for 
continuous variables; and sample proportions for discrete variables.    
 
For the subjects whose BHAPO and BHAAA were both measured, logistic regression modelling 
was used to compare the subjects whose BHAPO and BHAAA were both below 25th percentile 
and the rest. Odds ratios for SNPs were estimated adjusting for covariates sex, race, BHAPO, 
BMI at puberty onset.  Because we did not know the real underlying genetic model, we tested 
dominant, recessive, and additive genetic models. We then tested interactions of SNP*race and 
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SNP*sex while adjusting for the covariates. These interaction terms allowed us to determine the 
heterogeneity of the genotype effect on HGCF between males and females or between whites and 
blacks. Statistical significance level was at alpha 0.05.  All statistical analyses were performed 
using SAS software (version 9.2, SAS Institute Inc., Cary, NC, USA). 
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Results 
 
Characteristics of subjects  
We identified 245 subjects (n=121 for boys; and 124 for girls) who had body height both at 
puberty onset (BHAPO) and body height at adult age (BHAAA).  Of these subjects, 184 (75.1%) 
were whites, and 61 (24.9%) were blacks. 17 subjects (6.9%) had HGCF.  At puberty onset, the 
HGCF group and the non-HGCF group were comparable for variable age (years) (mean 10.9 ± 
SD 0.7 versus 10.9 ± 0.8), sex (male 52.9% versus 49.1%), race (white 94.1% versus 73.7%), 
BMI (kg/m2) (18.2 ± 2.7 versus 18.7 ±  3.2);  the HGCF group was statistically significantly 
lower in measures of height (cm) (133.1 ± 3.6 versus 147.2 ± 8.3, P<0.0001) and weight (kg) 
(32.3 ±  4.9 versus 41.0  ±  9.6,  P=0.0003) (Table 3-2).  At the time of BHAAA, the HGCF 
group and the non-HGCF group were also comparable for age (years) (mean 20.7 ± SD 2.9 versus 
21.4 ± 3.7), and BMI (kg/m2) (24.5 ± 3.9 versus 25.6 ± 5.5); the HGCF group was statistically 
significantly lower than the non-HGCF group in measures of adult height (cm) (160.4 ± 7.6 
versus 171.7 ± 9.8, P<0.0001) and weight (kg) (63.0 ± 9.5 versus 75.8 ± 18.1,  P=0.0044) (Table 
3-2). 
 
Genetic associations with HGCF  
Table 3-3 presents the results for SNPs that were statistically significantly associated with HGCF.  
Of the 31 SNPs, 8 SNPs were found significantly associated with HGCF (P<0.05) and presented 
either increased risk or decreased risk of HGCF: 4 SNPs (rs7642134 near gene VGLL, rs7647305 
near ETV5, rs9939609 near FTO, and rs6440003 near ZBTB38) were associated with increased 
risk of HGCF (ORs = 4.89, 12.0, 14.0 and 7.02, respectively). 1 SNP, rs987237 near TFAP2B 
was associated with a decreased risk of HGCF (OR= 7.02).  The rest 3 SNPs presented opposite 
directions of associations by sex:  rs7759938 near LIN28B presented increased risk for boys (OR 
= 53.6) but decreased risk for girls (OR = 0.03); in contrast, rs1042725 near HMGA2 and 
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rs4794665 near NOG presented decreased risk for boys (OR = 0.02 and 0.002, respectively) but 
increased risk for girls (OR= 4.55 and 3.74, respectively). The magnitude of estimated ORs 
ranged widely from 0.002 to 117.  Different genetic models (additive, recessive and dominant) 
were observed across these associations.  
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Table 3-1. Groups of SNPs associated with traits of age at menarche  
SNP 
Group 
SNP Locus Near Gene Function Major/Min
or Allele 
MAF Risk 
Allele
* 
Group A 
(n=16):  
associate
d with 
age at 
menarch
e 
rs466639 1q23.3 RXRG Intronic C/T 0.13 T 
rs172687
85 
2p16.1 CCDC85A Intronic A/G 0.17 A 
rs764213
4 
3p12.1 VGLL3 Intergenic G/A 0.43 A 
rs643842
4 
3q13.32 LOC1004216
70 
Intergenic A/C 0.46 A 
 
5q31.1 PHF15 Intergenic C/G 0.23 C 
rs107986
6 
7p14.1 INHBA Intergenic C/G 0.12 C 
rs782117
8 
8q21.11 PEX2  Intergenic C/A 0.42 A 
rs209040
9 
9q31.2 TMEM38B Intergenic C/A 0.39 A 
rs109809
26 
9q31.3 ZNF483 Intronic G/A 0.40 G 
rs108994
89 
11q14.1 GAB2 Intronic C/A 0.12 C 
rs658996
4 
11q24.1 BSX Intergenic C/A 0.48 A 
rs963575
9 
17q21.3
3 
CA10 Intergenic G/A 0.30 G 
rs139821
7 
18q21.1 SKOR2 Intronic C/G 0.40 G 
rs104236
74 
19p13.1
1 
CRTC1 Intronic C/A 0.39 C 
Group B 
(n=8):  
associate
d with 
age at 
menarch
e and 
BMI 
rs281575
2 
1p31.1 NEGR1 Intergenic A/G 0.36 A, A 
rs109134
69 
1q25.2 SEC16B Intronic T/C 0.25 C, C 
rs654823
8 
2p25.3 TMEM18 Intergenic C/T 0.15 C, C 
rs764730
5 
3q27.2 ETV5 Intergenic C/T 0.20 C, C 
rs109383
97 
4p12 GNPDA2 Intergenic A/G 0.45 G, G 
rs987237 6p12.3 TFAP2B Intronic A/G 0.16 G, G 
rs713880
3 
12q13.1
2 
FAIM2 Intergenic G/A 0.35 A, A 
rs993960
9 
16q12.2 FTO Intronic T/A 0.46 A, A 
Group C 
(n=7): 
associate
d with 
rs644000
3 
3q23 ZBTB38 Intronic A/G 0.43 G,G 
rs109468
08 
6p22.2 HIST1H1D Intergenic A/G 0.30 G, G 
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age at 
menarch
e and 
height 
rs775993
8 
6q16.3 LIN28B Intergenic T/C 0.36 T, C 
rs454963
1 
6q22.32 LOC728666 Intergenic C/T 0.46 C, T 
rs104272
5 
12q14.3 HMGA2 Intergenic T/C 0.49 T, T 
rs165912
7 
16p13.1
2 
MKL2 Intergenic G/A 0.30 G, G 
rs479466
5 
17q22 NOG Intergenic G/A 0.46 A, G 
rs757608 17q23.2 TBX2 Intergenic G/A 0.31 A, G 
rs480014
8 
18q11.2 CABLES1 Intronic A/G 0.24 A, G 
MAF: Major allele frequency; SNP: single nucleotide polymorphism 
* Risk allele refers to the allele that was associated with a younger age at menarche or at natural 
menopause in previous GWAS [Elks, 2010]  
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Table 3-2.  Characteristics of study subjects 
Characteristics  HGCF group  
(N= 17) 
Non-HGCF group  
(N= 228) 
P value 
At puberty onset * 
Age (years)  (Mean  ± 
SD) 
10.9 ± 0.7 10.9 ± 0.8 NS 
Sex [n, (%)] 
     Male 
 
9 (52.9%) 
 
112 (49.1%) 
 
NS 
    Female 8 (47.1%) 116 (50.9%)  
Race (n, %) 
    White 
 
16 (94.1%) 
 
168 (73.7%) 
 
NS 
    Black 1 (5.9%) 60 (26.3%)  
Height (cm)  133.1 ± 3.6 147.2 ± 8.3 <0.0001 
Weight (kg) 32.3 ± 4.9 41.0 ± 9.6 0.0003 
BMI  (kg/m2) 18.2 ± 2.7 18.7 ± 3.2 NS 
At time of BHAAA * 
Age (years) 20.7 ± 2.9 21.4 ± 3.7 NS 
Height (cm) 160.4 ± 7.6 171.7 ±  9.8  <0.0001 
Weight (kg) 63.0 ± 9.5 75.8 ± 18.1 0.0044 
BMI  (kg/m2) 24.5 ± 3.9 25.6 ± 5.5 NS 
BHAAA: body height at adult age (lastly observed body height for boys older than 18 years and 
girls older than 16 years)  
BMI: body mass index 
HGCF: height growth catchup failure 
Puberty onset: estimated when onset of breast enlargement or onset of testicular enlargement 
occurs (10.5 to 12.5 years old for the white boys, and 9.5 to 11.5 years for black boys; and 9.5 to 
11.5 years for white girls and 8.5 to 10.5 for black girls) 
SD: standard deviation 
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Table 3-3. Significant SNP associations with HGCF 
SNP Genetic 
model 
Effect 
allele 
OR  P-value P-Value for 
heterogeneity 
for sex 
difference 
P-Value for 
heterogeneity 
for race 
difference 
rs7642134 additive A 4.89 0.04 NS NS 
rs7647305 recessive C 117 0.03 NS NS 
rs987237 dominant G 0.05 0.04 NS NS 
rs9939609 dominant A 14.0 0.04 NS NS 
rs6440003 recessive G 7.02 0.05 NS NS 
rs7759938 recessive C 53.6 for 
male 
0.03 for 
female 
0.006 0.006 NS 
rs1042725 dominant T 0.02 for 
male 
4.55 for 
female 
0.02 0.02 NS 
rs4794665 dominant G 0.002 for 
male 
3.74 for 
female 
0.03 0.03 NS 
HGCF: Height growth catchup failure; 
OR: odds ratio estimated from logistic regression models 
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Discussion 
 
Epidemiology studies have been conducted to explore the association between genetic variations 
and adult height (Lui 2015; de Bruin 2016).  However, to our best knowledge, no studies were 
published on the association of genetic variations and catch-up in body height growth in 
adolescents who are relatively short in reference to their chorological age. Our study showed that 
8 SNPs previously found associated with age at menarche were also associated with HGCF 
(Table 3-3). In addition to originality in our study, our research is clinically important because, by 
using genetic variants from previous GWAS studies, we might be able to timely identify those 
adolescents who would remain relatively short from puberty onset to adulthood, and make them 
accessible to effective and efficacious treatments that would be otherwise missed.  Earlier data 
showed that by the time when the short adolescents received medical attention and started their 
growth enhancement, they were already on average older than 14 years old (Albanese 1995). 
These subjects could have passed the growth spurt period, and have missed their optimum timing 
for growth enhancement treatments (e.g., testosterone, and growth hormone) (Grimberg 2016; 
Kappy 2010). Starting the growth enhancement treatments late at this age partially explained the 
unsatisfactory treatment result for growth catch up in these adolescents (Albanese 1995). In 
recent years, younger ages at starting growth enhancement treatments (approximately 10 to 11 
years old) were observed (Şıklar 2015) probably because more parents started to bring their short 
children to medical attention at a younger age, and then have more accessibility to growth 
hormone therapy. By using the HGCF-associated SNPs as a biomarker, we would be able to 
practically restrict the growth enhancement treatments to the subjects who are likely to develop 
HGCF. Therefore, we would avoid the high costs of growth hormone therapy unnecessarily 
prescribed to those who can catch up in growth, and would save health resources. With insight in 
the SNPs associated with HGCF, we may also be able to identify those who appear short but 
would catch up in height growth, thus help mitigate concern and anxiety arising from being short 
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that is observable at puberty onset. Therefore, studying these SNPs associated with HGCF is 
valuable for improving clinical consultation and management.   
 
Of the 31 menarche-related SNPs, 8 SNPs were found significantly associated with HGCF 
(P<0.05). 1 of these 8 significant SNPs was from group A consisting of 16 SNPs associated with 
menarche only; 3 were from group B consisting of 8 SNPs associated with both menarche and 
BMI; and 4 from group C consisting of 7 SNPs associated with both menarche and height. The 
observed associations in various groups supported the hypothesis that the common genetic 
variants have pleiotropic effects on age at menarche, body growth in height, weight as well as 
HGCF.  
 
It is interesting that these 8 SNPs presented either increased or decreased risk of HGCF. SNP 
rs7642134 from group A presented an increased risk of HGCF (Table 3-3). This is plausible 
because high-level exposure to estrogen exists among the girls with menarche at a younger age 
(Onland-Moret, 2005) and presumably in the boys with menarche-associated genetic variants. 
The high-level estrogen promotes growth plate senescence at epiphyses of long bones. 
Consequently, it causes chondrocyte proliferation to stop at a younger age and results in a shorter 
adult height (Lui 2015). In other words, a delay in menarche or lack of menarche-associated 
genetic variation allows more growth of the long bones before the epiphyses closure and results 
in a taller adult height. A large epidemiology study including 286,202 European women subjects, 
showed that younger age at menarche was associated with shorter adult height (Onland-Moret, 
2005). Of note, we hypothesized the effects of menarche-associated SNPs are applicable to both 
girls and boys. Recently studies including one large-scale GWAS of puberty timing in men 
suggested overlapped gene loci between males and females and these shared loci were associated 
adverse health outcomes (higher BMI, polycystic ovary syndrome, type 2 diabetes, lipid profiles 
and cardiovascular disease) (Day 2015; Perry 2014; Ong 2009).  However, the rest 7 SNPs in 
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group B and C was either positively or negatively associated with HGCF (Table 3-3). The precise 
mechanisms of how these SNPs play their roles in developing HGCF are unknown.  Of note, the 
SNPs in the group B were previously associated both age at menarche and BMI, and the SNPs in 
group C were associated with both age of menarche and height. Therefore, it is speculated that, in 
addition to the role of estrogen, other common hormones (e.g., testosterone, growth hormone and 
insulin-like-growth factor-1 (IGF-1)) that regulate puberty development and body growth (linear 
height and BMI) are also involved in the process of reaching an adult height (Kappy 2010). These 
hormones could interact with estrogen in a sophisticated way that determines HGCF.  In group C, 
we observed the opposite associations by sex.  This suggested that the effects of these SNPs on 
HGCF, if any, could vary by sex. Again, the precise mechanism behind it is unknown. It is known 
that girls and boys differ in puberty onset timing and duration of growth spurt, all of which affects 
adult height (Kappy 2010 and Nelson 2016).  Further studies on how boys and girls differ in the 
SNPs roles in estrogen and androgen generation, and subsequent interaction with related growth 
pathway (e.g. growth-hormone-IGF-1 axis) as well as local growth plate at long-bone epiphyseal 
will advance our understanding about sex differences.   
 
Our study has the following limitations. First, the study was retrospective and should be 
considered exploratory for scientific assumption generation. We adjusted for a few covariates. 
However, important risk factors such as exercise, and nutrition were not available in this study. 
Thus, residual confounding could not be ruled out. Second, a small sample size is the major 
limitation. The findings from this study will be subject to replication and validation in large-
scaled studies with different study populations and different racial backgrounds. Also because of 
the small sample size, we cannot perform more clinically meaningful analysis by selecting those 
subjects who had a body height that remained much lower than 25th percentile from adolescence 
to adulthood and would draw much more medical attention.  For example, we could not have a 
sample size large enough for those with a body height < 1st percentile in reference to the CDC 
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growth chart for height from adolescence to adulthood, or <-2.25 standard deviation below the 
general population mean. The cutoff <-2.25 standard deviation sometimes is referred as clinical 
cutoff for idiopathic short stature that is reimbursable for growth hormone treatment by the US 
FDA (Foods and Drugs Administration) (Allen 2013). Also because of the small sample size, no 
effort was executed to account for multiplicity. Third, our study measures of BHAPO and 
BHAAA were limited by lack of direct measures of puberty onset and adult height because we 
did not have data on when testicular enlargement occurred in boys and breast buds (thelarche) 
occurred in girls, or bone age data indicating an adult height had been reached.  Nevertheless, our 
method of selecting those subjects who were consistently relatively short from early adolescence 
to adulthood should be considered robust because we selected those subjects whose body height 
can be reasonably estimated around the time of puberty onset (Kappy, 2010), and at the time 
when an adult height was likely to have achieved (CDC growth chart; Benabbad, 2016). Fourth, 
no precise biological mechanisms are known how these genetic variants played the role in HGCF.  
As recent meta-analyses suggested that adult height could be related to >600 hundreds of SNPs 
clustered in >400 different loci across the human genome, and these loci are enriched for genes 
that are connected to multiple biological pathways to height growth (e.g., growth hormone-IGF-1, 
transforming growth factor beta, C-natriuretic peptide signaling, rapamycin, osteoglycin, and 
hyaluronic acid) (Wood 2014, Lui 2015, De Bruin 2016), our effectors of studying only 31 SNPs 
appeared small. Before studying the precise mechanisms for these, we probably need to expand 
our study to include more height-associated SNPs from previous GWAS studies and evaluate if 
more SNPs are associated with HGCF.  However, our study can serve as a pilot study and give us 
clues for future researche.  
  
 55 
Conclusion 
 
Some but not all the genetic variants from previous GWAS that were associated with menarche 
age showed significant associations with HGCF in healthy adolescents. The results from this 
study suggest that the genetic variants associated with age at menarche, BMI and adult height 
may add value to clinical growth evaluation and management for the subjects at risk of HGCF. 
However, it is necessary to replicate and validate the results from this study by conducting further 
studies with larger sample sizes and different populations, and studies on mechanisms of how 
these genetic variants influence HGCF  
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